SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK
32.84
02-May-25 15:45:00
15 minutes delayed
Stocks
+0.39
+1.20%
Today's range
32.43 - 33.28
ISIN
N/A
Source
NASDAQ
-
17 Oct 2024 15:05:25 By Nasdaq GlobeNewswire
-
10 Oct 2024 16:12:14 By Nasdaq GlobeNewswire
-
24 Sep 2024 06:30:33 By Nasdaq GlobeNewswire
-
19 Sep 2024 15:30:44 By Nasdaq GlobeNewswire
-
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
28 Aug 2024 15:15:26 By Nasdaq GlobeNewswire
-
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
19 Aug 2024 06:00:51 By Nasdaq GlobeNewswire
-
Supernus Announces Second Quarter 2024 Financial Results
06 Aug 2024 15:06:00 By Nasdaq GlobeNewswire
-
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01 Aug 2024 15:30:11 By Nasdaq GlobeNewswire
-
23 Jul 2024 15:13:37 By Nasdaq GlobeNewswire
-
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 May 2024 15:25:33 By Nasdaq GlobeNewswire
-
23 May 2024 15:05:48 By Nasdaq GlobeNewswire
-
09 May 2024 15:05:39 By Nasdaq GlobeNewswire
-
Supernus Announces First Quarter 2024 Financial Results
08 May 2024 15:05:50 By Nasdaq GlobeNewswire
-
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
01 May 2024 07:00:32 By Nasdaq GlobeNewswire
-
24 Apr 2024 15:05:53 By Nasdaq GlobeNewswire
-
Supernus Provides Regulatory Update for SPN-830
08 Apr 2024 07:00:16 By Nasdaq GlobeNewswire
-
Supernus to Participate in Two Upcoming Investor Conferences
06 Mar 2024 15:30:50 By Nasdaq GlobeNewswire
-
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
28 Feb 2024 15:30:04 By Nasdaq GlobeNewswire
-
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 15:05:33 By Nasdaq GlobeNewswire
-
13 Feb 2024 15:05:20 By Nasdaq GlobeNewswire